GlaxoSmithKline
Company and Pharmaceutical Company
|
Ranbaxy takes on GSK's Valtrex in US...manufacturer entitled to offer an affordable alternative to the brand, Valtrex tablets by GlaxoSmithKline". With the launch, the company may beat its guidance of reporting a huge loss of around Rs 700 crore for the year, analysts... In this article: Valtrex, GlaxoSmithKline, Ranbaxy Pharmaceuticals, US Food And Drug Administration, Revenue, Herpes, and MAT |
-
Web Wire | 2 days ago
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries
WEBWIRE - Tuesday, November 24, 2009 GlaxoSmithKline (GSK) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement to commercialise Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B...
In this article: Tenofovir, Gilead, Asia, Adefovir, Taiwan, China, Chronic hepatitis, HIV Infection, and Nasdaq
-
Centre Daily Times | 2 days ago
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread® for Chronic Hepatitis B in Key Asian Countries
...Chronic Hepatitis B in Key Asian Countries FOSTER CITY, Calif. & LONDON - Gilead Sciences, Inc. (Nasdaq:GILD) and GlaxoSmithKline (NYSE:GSK) today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for...
In this article: Gilead, HBV, Tenofovir, Adefovir, Chronic hepatitis, Gilead Sciences, Asia, HIV, and Trademark
-
AP Online | 2 days ago
GlaxoSmithKline pulls swine flu vaccines in Canada
LONDON (AP) - The pharmaceutical company GlaxoSmithKline says it has advised medical staff in Canada to not use one batch of swine flu vaccine for fear it may trigger life-threatening allergies. GlaxoSmithKline spokeswoman Gwenan White...
-
Reuters | 3 days ago
UPDATE 1-Glaxo temporarily withdraws Avodart cancer filing
...or efficacy * Glaxo had filed for prostate cancer risk reduction Oct. 1 (Adds explanation for withdrawal, background) GlaxoSmithKline <GSK.L> temporarily withdrew its application to U.S. regulators for a new use of its Avodart drug in...
-
Winston-Salem Journal | 3 days ago
Drugmaker signs on with GlaxoSmithKline
...vaccine, took a big step toward its goal last week by striking a deal with pharmaceutical giant GlaxoSmithKline. Under the agreement, GlaxoSmithKline will pick up the cost of developing and marketing the vaccine, called NicVax, if...
In this article: Nicotine, Chantix, Tobacco, American Lung Association, Novartis, and Centers for Disease Control and Prevention
-
National Post | 6 days ago
GlaxoSmithKline shelves lot of H1N1 vaccine
...higher risk of adverse reactions, says a Manitoba health official. Dr. Joel Kettner, Manitoba's chief public health officer, said Thursday that GlaxoSmithKline has asked that the October batch be taken out of circulation because it produced...
In this article: Manitoba, Winnipeg Free Press, Winnipeg, and Canada
-
UPDATE 2-Nabi, Glaxo sign nicotine-addiction vaccine deal
...2010 * Nabi shares jump 26 pct (Adds details, share movement) Nabi Biopharmaceuticals <NABI.O> and a unit of GlaxoSmithKline Plc <GSK.L> signed a licensing agreement for Nabi's experimental vaccine to treat nicotine addiction and the...
In this article: Glaxo, Nicotine, London Stock Exchange, Nasdaq, and Novartis
-
Prime Newswire | November 16, 2009
GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction
...is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed...
In this article: Nicotine, Tobacco, Safe harbor, Fiscal year, Heroin, Dopamine, Royal College of Physicians, and Jean Stephenne
Trends
Loading...
More on GlaxoSmithKline
Description from Wikipedia:
GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a United Kingdom-based pharmaceutical, biological, and healthcare company. GSK is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
- Name:
- GlaxoSmithKline
- Type:
- NYSE: GSK)
- Location:
- Brentford, London, England, UK
- Founded:
- 2000, by merger of Glaxo Wellcome and SmithKline Beecham
- Stock Symbol:
- GSK
- Industry:
- Pharmaceutical
- Key People:
-
- Andrew Witty, Chief Executive
- Dr. Moncef Slaoui, Chairman of Research and Development
- Julian Heslop, Chief Financial Officer
- Sir Chris Gent, Chairman
- Products:
-
- Pharmaceuticals
- Central nervous system, respiratory, antiviral, antibiotic, oncology and emesis, metabolic, cardiovascular, urogenital, and over-the-counter medicines; vaccines; oral and nutritional healthcare products
- Revenue:
- £24.352 billion (2008)
- Operating Income:
- £8.259 billion (2008)
- Net Income:
- £4.712 billion (2008)
- No. of Employees:
- 103,000 (2008)
- Motto:
- "Do more, feel better, live longer"
Explore everything named GlaxoSmithKline...
